<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="132702">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01374282</url>
  </required_header>
  <id_info>
    <org_study_id>0172-001</org_study_id>
    <nct_id>NCT01374282</nct_id>
  </id_info>
  <brief_title>Post Marketing Surveillance Study of Cuprimine</brief_title>
  <official_title>Post Marketing Surveillance Study of Cuprimine (MK-0172-001)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <brief_summary>
    <textblock>
      Cuprimine (penicillamine) was made available in the Philippines by the Sponsor under a
      Compassionate Special Permit issued by the Bureau of Food and Drugs. Physicians were able to
      request the drug for their patients from the Sponsor. A Clinical Study Report form was
      completed for each purchase of Cuprimine.
    </textblock>
  </brief_summary>
  <overall_status>No longer available</overall_status>
  <phase>N/A</phase>
  <study_type>Expanded Access</study_type>
  <has_expanded_access>No</has_expanded_access>
  <condition>Scleroderma</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cuprimine (penicillamine)</intervention_name>
    <description>Dosage determined by the physician based on indication for treatment</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        - None

        Exclusion Criteria:

        - None
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>October 2015</verification_date>
  <lastchanged_date>October 21, 2015</lastchanged_date>
  <firstreceived_date>June 14, 2011</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Penicillamine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
